Eliaz Therapeutics Inc

Eliaz Therapeutics Inc is a biotechnology startup striving to revolutionize the treatment of life-threatening diseases with no effective current treatments. Founded in 2015 in the United States by Isaac Eliaz, MD, the company focuses on developing and commercializing a therapeutic Apheresis device that effectively removes Galectin-3 from the blood. Galectin-3 plays a causal role in numerous life-threatening inflammatory and fibrotic diseases, immune dysregulation, kidney deterioration, and cancer. The initial focus of Eliaz Therapeutics is on addressing Sepsis and Sepsis induced Acute Kidney Injury (AKI), conditions that have a significant impact on public health. With an annual US hospitalization rate for AKI in excess of 4,000,000 and deaths exceeding 500,000, the urgency in finding effective treatments is evident. Especially since Sepsis and AKI are increasingly recognized as in-hospital complications of various health conditions, including heart conditions, surgery, and COVID-19. Moreover, AKI is associated with long-term care, chronic kidney disease, hospital mortality, and higher healthcare costs. Eliaz Therapeutics' recent milestone includes a $1.70M grant investment from the National Institutes of Health in June 2022. This injection of funds serves as a testament to the significant potential of their approach and technology. With the potential to prevent, interrupt, or hasten recovery from sepsis and sepsis-AKI, the XGAL3 apheresis device holds promise in dramatic improvements in patient management and outcomes, potentially saving hundreds of thousands of lives per year.